LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Spero Therapeutics, Inc. ("Spero" or "the Company") (NASDAQ: SPRO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between October 28, 2021 and May 2, 2022, inclusive (the ''Class Period''), are encouraged to contact the firm before July 25, 2022.

More on iSports Wire

• Currier, de Snoo, Vinc Win NLL Transition, Defensive Player, Goaltender of the Year Awards
• America's Boating Channel Supports Operation Dry Water
• RealResponse Enters Professional Baseball With Major League Baseball Agreement
• New Factbook Delivers First Reference Compilation for 2022 Russia-Ukraine War
• Mutual Aid Ambulance Service Partners with Excela Health for Paramedic Training Program

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

More on iSports Wire

• First Winner-Take-All $250,000 OBL Finals Headed to The Dollar Loan Center in Las Vegas July 15-16
• In2Scuba Diving Co. of Maui introduces its exclusive beginner scuba diving lessons
• Boise Black Rifle Now Has a Silencer Shop Kiosk
• Always Ontime: Chaos City - Super Hero Graphic Novel with Neal Adams Cover Launches from Panopolis Metaverse
• Kelusky, Dietrich, Dawick, Gregoire, Lyle & Jeremy Thompson Nab Honors As NLL Opens Awards

According to the Complaint, the Company made false and misleading statements to the market. Spero submitted insufficient data to the FDA as part of its Tebipenem HBr NDA. It was unlikely that the NDA would receive FDA approval based on this deficiency. The Company would likely need to restructure and reduce its workforce due to the deficiency. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Spero, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts

The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

---

Show All News | Report Violation